EGFR and cancer: The anti-tumor effects of EFEMP1 in most cancer types are most likely accounted for by its anti-angiogenic effect [7], its anti-EGFR/AKT-mediated growth signaling effect [8–11], and its anti-IGF1R [12] and/or anti-TGFbeta [13] mediated epithelial-to-mesenchymal transition effects, as well as its function in normal tissue to inhibit the expression and activities of matrix metalloproteinase [14].